Civic AI
Procurement intelligence
Federal contract award
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
SEQIRUS INC · Department of Health and Human Services
- Value
- $450,052
- Start
- Apr 2, 2026
- End
- Nov 8, 2026
- Action date
- Apr 3, 2026
- PIID
- 75A50126F61013
- Status
- active
- NAICS
- 325414 · BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
- Place of performance
- HOLLY SPRINGS, NC
- Award type
- DELIVERY ORDER
Description
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
Need modifications, related awards, and vendor peers? Open the full award workspace.